Increased government focus on metabolic disease management and strategic investment by global pharma companies are accelerating product launches and adoption across the region
[3] As of mid-2025, retatrutide has not been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA) for use in the UK or Europe
Interestingly, its also showing significant potential in helping individuals manage their weight, making it a dual-purpose treatment
Curr Med Chem 12(23):27712794 Brandao R, Santos FW, Zeni G, Rocha JB, Nogueira CW (2006) DMPS and N-acetylcysteine induced renal toxicity in mice exposed to mercury
Kepka A, Ochocinska A, Borzym-Kluczyk M, Skorupa E, Stasiewicz-Jarocka B, Chojnowska S, Waszkiewicz N (2020) Preventive role of L-carnitine and balanced diet in alzheimer's disease